Healthcare
Resverlogix Corp.(RVXCF)
Live Price
Offline$0.07
+0.00% today
1Y Change
+133.33%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- $20.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -0.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Resverlogix Corp. (RVXCF) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.07 and up 133.3% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -0.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -0.4%, free cash flow +14.3% with operating margin 0.0% and ROIC 33.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVXCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -0.4%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 7, 2026 | โ | +0.0% | +0.0% | -12.5% |
2026 Mar 31, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Aug 14, 2025 | โ | +0.0% | +14.3% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVXCF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RVXCF Max Drawdown
-70.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RVXCF and SPY.
Company Overview
Resverlogix Corp.
Other OTC
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
- Leadership
- Donald J. McCaffrey
- IPO Date
- Feb 13, 2009
- Employees
- 19
- Street Address
- 4820 Richard Road SW
- Mailing
- Calgary, AB, T3E 6L1
- Region
- Calgary, AB, CA
- Reporting Currency
- USD
- Investor Line
- 403-254-9252
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -0.4%
- Free Cash Flow
- +14.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 8.4%
- ROIC
- 33.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.